Karen Carey

Repligen's Secretin Fails Autism Phase III; Subgroup Has Promise

Jan. 6, 2004

The new year greeted Repligen Corp. with disappointing data from its Phase III trial of synthetic human secretin in autism. (BioWorld Today)

ILEX Starts Clofarabine Filing Process, Begins Rolling NDA

Oct. 23, 2003

By Karen Carey

In a move to launch its second product in the U.S., ILEX Oncology Inc. filed the first part of a rolling new drug application on Wednesday for Clofarabine to treat refractory or relapsed acute leukemia in children.(BioWorld Today)

Cypress Bioscience Begins Milnacipran Phase III Trial

Oct. 22, 2003

By Karen Carey

Genelabs Rakes In $27.4M For Prestara, Hepatitis C Programs

Oct. 20, 2003

By Karen Carey

Advancis IPO Raises $60M; Biotech Firms Wait In Wings

Oct. 20, 2003

By Karen Carey

Cardiome Pharma, Fujisawa Enter $68M Cardio Drug Deal

Oct. 17, 2003

By Karen Carey

With Two Products In Clinic, GTx Seeking $86.25M In IPO

Oct. 17, 2003

By Karen Carey

Immunex, Abgenix Revise Plans To Advance ABX-EGF For Cancer

Oct. 16, 2003

By Karen Carey

CoTherix Acquires Schering's U.S. Rights For Ventavis, Raises $55M

Oct. 15, 2003

By Karen Carey

The company formerly known as Exhale Therapeutics Inc. has acquired a new name, a new financing and new U.S. rights to a pulmonary hypertension product. (BioWorld Today)